Selective Phosphodiesterase 4B Inhibitors: A Review

Abstract Phosphodiesterase 4B (PDE4B) is a member of the phosphodiesterase family of proteins that plays a critical role in regulating intracellular levels of cyclic adenosine monophosphate (cAMP) by controlling its rate of degradation. It has been demonstrated that this isoform is involved in the orchestra of events which includes inflammation, schizophrenia, cancers, chronic obstructive pulmonary disease, contractility of the myocardium, and psoriatic arthritis. Phosphodiesterase 4B has constituted an interesting target for drug development. In recent years, a number of PDE4B inhibitors have been developed for their use as therapeutic agents. In this review, an up-to-date status of the inhibitors investigated for the inhibition of PDE4B has been given so that this rich source of structural information of presently known PDE4B inhibitors could be helpful in generating a selective and potent inhibitor of PDE4B.


Introduction
Phosphodiesterases (PDEs) are a diverse family of enzymes involved in phosphoric diester hydrolytic cleavage. The term, however, is usually applied to phosphodiesterases that cleave cyclic nucleotides that are important for transmitting signals within the cell. These enzymes are known as cyclic nucleotide phosphodiesterases (PDEs). There are other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases. Cyclic nucleotide PDEs constitute a superfamily of enzymes which catalyze the hydrolysis of 3',5'-cyclic adenosine monophosphate (cAMP) and 3',5'-cyclic guanosine monophosphate (cGMP) to their inactive 5′-AMP and 5'-GMP forms, respectively. In mammals, PDE enzymes are classified into 11 families, namely PDE1-PDE11. PDE4 is differentiated from other PDEs by its high sensitivity towards the inhibitors, and because of its potential use in the treatment of depression and schizophrenia [1,2].
PDE4 is the major cAMP-metabolizing enzyme found in inflammatory and immune cells [3,4]. The PDE4 family encompasses four genes coding the subtypes PDE4A, PDE4B, PDE4C, and PDE4D [5], but the PDE4B subtype is believed to play a central role in inflammation [6], being the predominant subtype in monocytes and neutrophils. All four PDE4 subtypes comprise a related structural organization with a highly conserved catalytic domain in the C-terminal region and upstream-conserved regions in the N-terminal portion of the protein [5]. The high-resolution structures of PDE4B complexes are presented and provide an insight into understanding the substrate and inhibitor binding as well as the critical function of metal ions [7,8]. PDE4B comprises three domains: an N-terminal regulatory domain, a catalytic domain of about 300 amino acids, and a C-terminal domain. The catalytic domain is the most conserved domain among the PDE families and consists of 17 α-helices. Several reviews on PDE4 have appeared in articles [9][10][11][12][13][14][15][16] covering the role of phosphodiesterase-4 inhibitors in the treatment of asthma, chronic obstructive pulmonary, psoriasis, psoriatic arthritis, chronic inflammatory, autoimmune, and inflammatory bowel diseases. In this review, we present the most significant examples of PDE4B inhibitors that exhibit various biological activities reported in literature.

Selective PDE4B Inhibitors
The design of selective PDE inhibitors started in 1958 when Sutherland and Rall [17] identified the enzymatic activity of phosphodiesterases and its biochemical importance. These cyclic nucleotide levels play an important role in many mammalian physiologies ranging from immune and inflammatory responses [18], regulation of the contractility of the myocardium and smooth muscles [19], to depression and cognition [20]. These centric roles of cAMP initiated research efforts in developing selective inhibitors of PDEs such as vinpocetin for PDE1, inamrinone, milrinone, enaximone for PDE2, rolipram, cilomilast, roflumilast for PDE4, and sildenafil for PDE5 [21]. A pharmacological study in mice proved that PDE4B mediates antipsychotic effects [22,23] by its role in dopamine-associated and stress-related processes. PDE4B is the only subtype of PDE4 expressed in the locus coeruleus, a region in the brain that is rich in nonadrenergic neurons that mediates some anti-depressant effects [24] and it is the only isoform of PDE4 expressed in the white matter of the brain. PDE4B is also involved in schizophrenia [25] and anxiety [26]. In contrast to PDE4B, PDE4D is expressed in the area postrema and nucleus of the solitary tract [27,28], which are responsible for emesis.
The first generation the PDE4 inhibitor rolipram was withdrawn for its potent action on the PDE4D isoform, which is likely to be implicated in emesis [30]. PDE4B is abundant in inflammatory, immune, and airway smooth muscle cells [31] and thoroughly investigated for treating inflammatory pulmonary disorders [11]. Further, gene knockout studies proved that PDE4B could suppress TNF-α production [32] and has been investigated as an attractive and excellent therapeutic target due to its sensitivity to selective inhibitors Sci Pharm. 2014; 82: 453-481 [33][34][35]. In the year 2004, a high throughput screening resulted in the identification of the lead compound 1a (Figure 1), which exhibited significant PDE4B inhibition (pIC 50 6.8) [36]. A high temperature reaction between N-1-ethyl-5-aminopyrazole and diethyl ethoxymethylenemalonate resulted in the formation of the intermediate 4-hydroxypyrazolopyridine, which upon treatment with phosphoryl chloride gave the 4-chloro-derivative. Treatment of the 4-chloro-derivative with a diverse range of amines yielded 2a-g ( Figure 1) via thermal displacement [37]. Structure-activity data showed a significant increase in the potency with a branched or cycloalkyl amino group at fourth position of the pyridine nucleus, with 6-membered saturated rings being more potent than 5-membered rings. Tertiary amines such as pyrrolidine in 1c and the N-methylated analogue such as 1e were less tolerated and suggested the importance of the NH group. These observations were further supported by crystal structures of the pyrazolopyridine analogue 3a (Figure 1) bound to PDE4B 152-503 (PDB ID: 3D3P), which showed the tetrahydropyran moiety towards the metal ions. An intramolecular hydrogen bond between the 4-amino NH group and the carbonyl of the amide was observed, which maintained the co-planarity with the template. Unbranched alkyl amines gave poor selectivity in comparison to the branched analogues, which routinely gave >100-fold selectivity. (1) ; Fig. 1.

Structure of various congeners of pyrazolopyridine with PDE4B inhibitory activity
The structure-activity relationship is further exemplified by varying the substituent at first position of the pyrazolopyridine ring 2. However, the simple alkyl and aryl substituent on first position did not yield selective PDE4B inhibitors, except for the hydroxyethyl substituent in the pyrazolopyridine derivative 2e, which exhibited a similar pIC 50 of 6.8 as that of the lead molecule. Introduction of the amide function at fifth position retained PDE4B selectivity and secondary amides were well-tolerated because of their lipophilic nature, while benzyl amide derivative 3a and saturated analogues such as 3b showed enhanced inhibitory activity on PDE4B with pIC 50 values of 8.5 and 8.1, respectively. Primary amide 3c showed significant inhibition (pIC 50

Fig. 2.
Analogues of 2-arylpyrimidines with PDE4B inhibitory activity In the year 2009, 2-arylpyrimidine derivative 4a ( Figure 2) was identified as a selective and potent PDE4B inhibitor with an IC 50 of sub-micromolar range (0.19 µM) and a potential 10fold selectivity over PDE4D [38]. Authors further investigated the structure-activity relationship to optimize this lead compound which afforded a series of potent PDE4B inhibitors with >100-fold selectivity over the PDE4D isozyme. With a good pharmacokinetic profile, the selected compound exhibited potent anti-inflammatory properties. The compounds bearing allyl (4a), ethyl (4b), cyano (4c), or formyl (4d) groups at fifth position of the pyrimidine ring were found to be equipotent for PDE4B inhibition (pIC 50 190, 140, 120, and 300 nM, respectively) and 4B/4D selectivity. Bulkier groups at this position reduced the potency in derivatives 4f (PDE4B pIC 50 1300 nM), 4g, 4h, and 4j (PDE4B pIC 50 >1000 nM in all three compounds). Derivative 4k, having an ethyl group at sixth position of the pyrimidine ring, showed enhanced potency (PDE4B pIC 50 34 nM), but less selectivity compared with the methyl analog 4a. Authors also explored the SAR at second position of the pyrimidine ring. Potency and selectivity towards PDE4B was retained when the phenyl ring at second position of the pyrimidine ring was substituted with 2-thienyl 5a ( Figure 2) (PDE4B pIC 50 120 nM) or 3-thienyl 4b (PDE4B pIC 50 68 nM) groups. However, substitution of thiazol-4-yl 5c (PDE4B pIC 50 2800 nM), 2-pyridyl 5d (PDE4B pIC 50 3700 nM), or pyradinyl 5e (PDE4B pIC 50 860 nM) groups at the same position markedly reduced the potency. Similar results were observed when the phenyl ring was substituted at second position of the pyrimidine ring and a carboxymethyl group at fourth position of the aminophenyl moiety present at fourth position of the pyrimidine ring (6a) ( Figure 2). However, compounds 6c and 6d, possessing a substituted thienyl group at R 1 and a carboxymethyl group at second position of pyrimidine ring, showed more than a 25-fold selectivity towards PDE4B. Further modification of the above compounds resulted in compounds 7a-d ( Figure 2), which showed potent inhibitory activity on PDE4B (pIC 50 15 nM, 6.8 nM, and 15 nM, respectively) and >100-fold selectivity over PDE4D (PDE4B pIC 50 1700 nM, 2900 nM, 3100 nM, respectively).

Fig. 3.
Analogues of 3-aminocarboxy-4-anilinoquinoline with PDE4B inhibitory activity In another communication, the discovery of 3-aminocarboxy-4-anilino quinoline 8 ( Figure  3) as a potent and selective PDE4 inhibitor (PDE4B pIC 50 8.4) is described [39]. Further structural modification of compound 8 has been carried out and the structure-activity relationship of a novel series of quinoline-3-carboxamides 9a-d ( Figure 3) at fourth, sixth, and 8-methyl compounds is described by the authors. A further compound, 9d (GSK256066), was identified as a highly potent PDE4 inhibitor suitable for inhaled administration, which also inhibited the LPS-induced production of TNF-α from isolated human peripheral blood mononuclear cells with a pIC 50  bioavailability in rats. The crystal structure of GSK256066 bound to PDE4B was also obtained to 1.75 Å resolution (PDB ID: 3GWT).
By high throughput screening, tetrahydrobenzothiophene (THBT) bisamide (10) (Figure 4) was discovered to be a potent and modest PDE4B over the 4D-selective inhibitor (PDE4B/4D pIC 50 6.7/6.5) [40]. Authors investigated the HBT binding mode with the ligand/PDE4B catalytic domain of the available co-crystal structure (PBD ID: 3HMV) [41] to design the analogue having PDE4B selectivity over PDE4D. Furthermore, based on the binding mode at the active site of PDE4B, disubstituted-4,5,6,7-tetrahydro-1benzothiophene-3-carboxamides 11 ( Figure 4) were synthesized and evaluated for their binding affinity to the PDE4B isoenzyme. Authors disclosed the structure-activity relationship at 3-carboxy and around the tetrahydrobenzo groups. Potencies significantly reduced when the primary amide was methylated and indicated a clear requirement for the primary carboxamide at third position. Structural modification around the tetrahydrobenzo group confirmed the 4B-subtype selectivity and indicated a preference for small C6 substituents. Moreover, the maximum potency and 10-fold selectivity was observed in the compound where R 2 = 6-ethyl. In search of new compounds to treat inflammation, the pyridazino[4,5-b]indolizine analogue 12a ( Figure 5) was found to possess a 23-fold selectivity for PDE4B (K i 2.60 lM) over PDE4D [42]. In order to improve potency and selectivity, the substituted phenyl analogues 12b-g were prepared and comparable results were obtained from a cell-based adenylyl cyclase functional assay (PDE4B, IC 50 13.2 µM; PDE4D, IC 50 >100 µM). Interestingly, the fluorine-substituted analogue 12e was found to have high selectivity towards PDE4B compared to the derivative 12a. In N-acetyl piperazine analogue 13 ( Figure 6), the electron-withdrawing substituent on the 3-position of benzene significantly increased the PDE4B inhibitory potency (PDE4B K i 1.90 µM). 1,2-Dimethyl-1H-pyrrolo[2,3d]pyridazine analogues 14a-d ( Figure 6) were synthesized and evaluated for the selective affinity for PDE4B compared to PDE4D. Results revealed that -Cl and -Br substituents, respectively, at second and fourth position of the phenyl ring reduced the PDE4B affinity.
In continuation of the above work [42], two 1,2-dimethyl-1H-pyrrolo[2,3-d]pyridazine analogues, 15a and 15b ( Figure 6) have been reported to possess greater affinity as well as selectivity for PDE4B. However, the analogue 15b having the 3-NO 2 -C 6 H 5 substituent on seventh position of the pyrrolo[2,3-d]pyridazine ring showed poor oral bioavailability in the pharmacokinetic study. On the other hand, unsubstituted analogue 15a exhibited an impressive 205-fold selectivity for PDE4B when compared to PDE4D.
A novel series of 3,5-disubstituted-1,2,4-oxadiazoles 20a-g ( Figure 9) has been prepared and evaluated for PDE4B2 inhibitory activity [47]. Among the synthesized compounds, 20a exhibited maximum PDE4B2 inhibition (IC 50 5.28 lM). A structure-activity relationship study revealed that the substituents 3-cyclopentyloxy-4-methoxyphenyl group at third position and the cyclic ring bearing heteroatoms at fifth position of the 1,2,4-oxadiazole ring are important for activity. The molecular modeling study showed similar interactions of the 3-cyclopentyloxy-4-methoxyphenyl group compared to the piclamilast. However, the heteroatom ring was found to be slightly deviated compared to piclamilast. Compound 20a exhibited significant analgesic and anti-inflammatory activities in the formalin-induced pain in mice and carrageenan-induced paw edema model in rats.   Figure 12) were synthesized through Pd/C-Cu catalysis as a new class of PDE4B inhibitors [50]. Synthesized compounds were evaluated against the PDE4B enzyme isolated from Sf9 cells and results were compared with the reference compound rolipram, a well-known inhibitor of PDE4. All compounds showed significant inhibition (>70%) of PDE4B when tested at 30 µM. A dose-response study was also carried out using compound 27 which showed dose-dependent inhibition of PDE4B. It is well-known that inhibition of the PDE4D subtype is linked to the emetic response [51]; hence, compounds 24-27 were tested for their PDE4B selectivity over PDE4D. Tested compounds showed 20-30% inhibition at 30 µM indicating their approximately two-fold selectivity towards PDE4B. The in silico docking study result of compound 25 showed the interaction of the hydroxyl function of Tyr233 with pyrazole nitrogen, the π-π stacking interaction between the pyrazole ring and His234, coordinate interaction between the Mg +2 ion and the ester carbonyl function, and coordinate interaction between the Zn +2 ion and pyrazole nitrogen. On the other hand, the π-π stacking interaction between pyrazole and His234 and the coordinate interaction between Mg ++ and the ester carbonyl group was observed in compound 26. Green synthesis of functionalized cyano pyridines 28a-e ( Figure 13) as novel PDE4B inhibitors has been described via the montmorillonite K-10-mediated multi-component reaction in a chemo-and regioselective manner [52]. The synthesized compounds were evaluated for their PDE4B inhibitory potency at 30 µM using rolipram as the standard. The in vitro results revealed that a strong electron donating group such as OCH 3 at the para position of the benzene ring in 28a (percentage inhibition 64.10) and 28b (percentage inhibition 65.0) was optimum for the activity compared to other milder electron donating groups such as F or Br (28c-e) (percentage inhibition <45). The di-or tri-substitution on the C-4 benzene ring resulted in the loss of PDE4B inhibitory activity. In silico docking studies showed the binding affinities of compounds 28a and 28c with a docking score of −25.47 and −17.8 kcal/mol, respectively. The cyano group of compound 28c formed Hbonding with HIS234 of the PDE4B isoenzyme. However, it was the OCH 3 group in 28a that formed H-bonding with the Glu443 residue of PDE4B. In addition, it also showed an arene-arene interaction with the Phe446 residue.   Figure 14) have been explored as potent PDE4B inhibitors [39] (pIC 50 8.0-8.7 and 7.8-9.4, respectively) taking into account the discovery of 4-(substituted amino)-1-alkyl-pyrazolo[3,4-b]pyridine-5-carboxamides as potent and selective PDE4B inhibitors [37]. The structure-activity relationship of fifth 5-position was studied [53] further. Preliminary structure-activity studies were conducted against isolated PDE4B, the predominant PDE4 subtype in inflammatory cells of interest. Results indicated that both oxadiazole isomers were tolerated at fifth position. Different oxadiazole substituents showed significant potency in each series, but unfortunately no structure-activity relationship was established. Further di-substituted and mono-substituted oxazoles 31a and 31b ( Figure 14) were also synthesized. The di-substituted oxazole 31a demonstrated sub-nM activity in the isolated enzyme and isolated human peripheral blood mononuclear cells (PBMC) assay and gave at least a 10-fold increase in potency over 1,3,4-oxadiazole 13c and 1,2,4-oxadiazole 29b. Moreover, in compound 31a, the introduction of a second substituent showed an increase in potency in comparison to the mono-substituted oxazole 31b.
In the year 2013, compound 32 ( Figure 15) was identified as an orally active PDE4Bselective inhibitor over PDE4D both in humans (80-fold selective) and mice (29-fold selective) [54]. The therapeutic effect of compound 32 was evaluated on lipopolysaccaride (LPS) injection-induced plasma TNF-α elevation and on LPS inhalation-induced pulmonary neutrophilia in mice. The therapeutic index for TNF-α production (TI TNF = ID 50 in gastric emptying/ID 50 in LPS injection-induced plasma TNF-α elevation) of compound 32 was larger than roflumilast (9.0 and 0.2, respectively), whereas the therapeutic index for pulmonary neutrophilia of compound 32 was comparable to roflumilast (1.0 and 0.5, respectively). Authors disclosed that the TI TNF of compound 32 was not superior compared to that of roflumilast in spite of its high selectivity for PDE4B over PDE4D in mice. and TNF-α (IC 50 3.0 nM). The 5-carbamoyl moiety of compound 37 exhibited a waterbridged hydrogen bonding network with Asn395 and Gln443 residues in an X-ray crystallography study. In derivatives 36a-c, substituents hindered these interactions and this may be the reason for the lowered potency. The higher potency of 37 is further supported by the lengthy neopentyl substituent which fits into the lipophilic pocket.  One-pot synthesis of benzofuran fused N-heterocycles 39 and 40a-g ( Figure 18) has been achieved by AlCl 3 -mediated C-C followed by C-O bond formation between 2,3-dichloropyrazine or its derivatives and phenols. Synthesized compounds were tested in vitro for their PDE4B inhibitory activity [57]. Compound 39 showed significant PDE4B inhibition at 30 µM in comparison to the reference compound rolipram. Compounds possessing a substituent on the benzofuran moiety showed moderate activities and the presence of a smaller substituent was well-tolerated compared to a larger or bulky group in terms of PDE4 inhibition.  Figure 19) have been designed as potential inhibitors of PDE4. Designed compounds were synthesized in a multi-step reaction process involving the construction of a 1-nitro-10H-phenoxazine ring and then fusion with an imidazole ring as the key steps [58]. Some of these compounds showed promising in vitro PDE4B and D inhibition when tested. Compounds bearing 2hydroxyphenyl (41a), 2-bromophenyl (41b), and 5-bromo-2-fluorophenyl (41c) exhibited dose-dependent inhibition of PDE4B with IC 50 values of 3.31 ± 0.62, 1.23 ± 0.18, and 0.53 ± 0.18 µM, respectively. The interaction of compound 41a with the PDE4B was mainly contributed by H-bonding between the amino group of 41a with His-278,H-bonding between the hydroxyl group of 41a and Asp392, and two π-π stacking interactions between the benzimidazole moiety and His234. Similarly, the interaction of compound 41b with the PDE4B was contributed by H-bonding between the NH 2 -group of 41b and Thr345, as well as Asp392, π-π stacking interactions between the central 1,4-oxazine ring and Tyr233, and π-π stacking interactions between the phenyl group of 41b and Phe446. In compound 41c, H-bonding between the amino group and Asp275 and π-π stacking interactions between the aromatic ring system and Tyr233, His234, and Phe446 residues of PDE4B was observed. Selective PDE4 inhibitors exhibit antiproliferative activity against T-cells and B-cells and this finding helped researchers to investigate the selective PDE4 inhibitors as novel anticancer agents. This was further supported by the antiproliferative activity of PDE4 inhibitors against murine carcinoma cells [62]. PDE4 inhibitor rolipram induced cell cycle arrest and apoptosis [63], and overexpression of PDE4B resulted in diffuse large cell lymphoma (DLBCL); a fatal malignancy indicating that PDE4B inhibitors could be useful anticancer agents [64]. Moreover, PDE4B selective inhibitors were reported for selective apoptosis in malignant cells without affecting the normal cells. Based on these facts, novel PDE4B inhibitors were developed and screened for anticancer activity [65].
In the year 2013, novel N-[(1-substituted-1H-1,2,3-triazol-4-yl)methyl]-N-2,2,4-trimethyl-7phenoxy-1,2-dihydroquinolinemethanesulfonamides 48a-e ( Figure 23) were synthesized as selective PDE4B inhibitors. The reaction was carried out in aqueous DMF via a multistep sequence consisting of copper-catalyzed azide-alkyne cycloaddition (CuAAC) as the key step [66]. The compounds were evaluated in vitro for their cytotoxic activity using the lung adenocarcinoma epithelial cell line (A549), prostate cancer cell line (DU145), cervical cancer cell line (HeLa), and hepatocellular liver carcinoma cell line (HepG2) in an MTT assay. Among the synthesized inhibitors, 48a and 48b showed promising activity against the human lung cancer cell line (A549) with an IC 50 of 8-9 µM. Although compounds 48b, 48d, and 48e were identified as potent PDE4B inhibitors, they showed no cytotoxic activity towards the tested cancer cell lines. The docking results of the synthesized compounds revealed a high binding affinity of compound 48d with 1XMY (PBD ID). Hydrogen bonding with HIE-234 and π-π stacking interactions with PHE446 residues were also observed.  The novel nimesulide-based new class of triazole derivatives 49a-d ( Figure 24) were synthesized as PDE4B inhibitors [67]. The synthesized compounds were tested against cancer cells, keeping in view the reported anticancer activity of nimesulide [68] and the anti-inflammatory activity of 1,2,4-triazoles [69]. Some of the synthesized compounds exhibited significant in vitro PDE4B inhibitory properties with >50% inhibition at 30 µM. Moreover, results were also supported by the docking studies. The in vitro anticancer activity was evaluated using the HCT-15 human colon cancer cell lines with doxorubicin [IC 50 50 µg/mL, (0.09 µM)], an anthracyclin antibiotic as the reference compound. Two of the synthesized compounds 49c and 49d exhibited IC 50 values in the range 21-22 µg/mL. Docking results of synthesized compounds revealed similar interactions with Gln443 as that of rolipram. Apart from Gln443, compound 49a also exhibited interactions with His234 and His278, whereas compound 49b and 49c showed binding affinity for Asn283.
During cardiac action potential, Ca 2+ influx through the sarcolemma L-type Ca 2+ channels (LTCC) triggers Ca 2+ release from ryanodine receptor 2 located in the sarcoplasmic reticulum; this results in elevated Ca 2+ throughout the cell leading to contraction of the myocardium. PDE4 is one of the main PDEs expressed in the heart. PDE4 becomes predominantly active upon β-adrenergic receptor stimulation and regulates LTCC and cAMP levels in cardiomyocytes [70][71][72][73][74][75]. In PDE4B-deficient mice, increased expression of the β-adrenoreceptor along with LTCC was observed leading to elevated intracellular Ca 2+ and cell contraction [76]. In another study, a novel series of 1,4-dihydropyridine-based PDE4B inhibitors were synthesized [77] and evaluated for their in vitro Ca 2+ channel blocking and PDE4B inhibitory activities. Compounds 50a-g ( Figure 25) exhibited >80% inhibition of PDE4B. Among the synthesized inhibitors, 50d, having an indaloyl moiety, exhibited significant selectivity towards PDE4B with a docking score of −8.1 kcal/mol. The in silico docking result of compound 50d supported the reason for the selectivity, where the indole moiety exists in two different orientations in PDE4D, and in both cases, it makes a stronger hydrogen bond with Glu396 or Glu505 residues of PDE4D, while its orientation in PDE4B is completely different than that in PDE4D. The dimethoxy group of 50d interacted with the metal atoms in PDE4B, while the indole moiety was shown to be H-bonded with the Ser442 backbone.
In recent research [78], authors disclosed that PDE4B selectivity can be achieved by the capture of a C-terminal regulatory helix, known as CR3 (control region 3), across the active site in a conformation that closes access by cAMP. PDE4B selectivity is driven by a single amino acid polymorphism in CR3 (Leu674 in PDE4B1 versus Gln594 in PDE4D). A new co-crystal structure with a bound ligand was developed which provided a guide map for the design of PDE4B-selective anti-inflammatory drugs. The comparative binding modes of the 2-arylpyrimidine derivative with PDE4D (PDB: 3G58), NVW-PDE4B (PDB: 3W5E), and OCP-PDE4B (PDB: 3KKT) structures showed that small molecules can interact with different residues of the CR3 helix resulting in multiple closed conformations.
The study highlighted the significance of (PDE4B Leu674/PDE4DGln594 and PDE4B Met675/PDE4D Thr595) that is essential to engage the ligand and/or catalytic domain.

Conclusion
Advancements in PDE4B selective-targeted therapies have shown promise in recent years for the treatment of inflammation, chronic obstructive pulmonary disorders, cancers, and myocardium contractility disorder. After the development of the prototypic PDE4 inhibitor rolipram, more selective inhibitors targeting the PDE4B isozyme have been widely investigated. However, the biological activity of this class of compounds deserves further investigation. This is evident when inflammatory diseases are considered. Although the research on this subject is incipient, the number of reports disclosing the effects of PDE4B inhibitors on TNF-α production and Ca 2+ channel blockage has recently been increasing. PDE4B selective inhibitors have been shown to be promising, which calls for the design of more efficient anti-inflammatory, anticancer, and cardio-protective agents. Although some patterns appear relating the structure and the pharmacological field, this also should be considered when designing new selective PDE4B inhibitors.